应用 |
A selective inhibitor of JAK2 mutant V617F. |
产品介绍 |
LY2784544是一种有效的JAK2抑制剂,IC50为3 nM,作用于JAK2V617F有效,比作用于JAK1和JAK3选择性高8和20倍。Phase 2。 |
备注 |
LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2. |
生化机理 |
LY2784544 is identified as being highly selective inhibitor of JAK2 mutant V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders. |
别名 |
3-[(4-氯-2-氟苯基)甲基]-2-甲基-N-(5-甲基-1H-吡唑-3-基)-8-(4-吗啉甲基)咪唑并[1,2-b]哒嗪-6-胺;LY 2784544; LY-2784544;3-[(4-Chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)imidazo[1,2-b]pyridazin-6-amine; |